The EPHX1 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout population derived from the Raji human B lymphocyte line, providing a heterogeneous pool with targeted EPHX1 gene disruption. This product enables investigation of microsomal epoxide hydrolase function in epoxide metabolism and B-cell lymphoma biology, with the polyclonal format retaining genetic diversity for robust functional assays.
Raji cells are an EBV-positive Burkitt’s lymphoma B lymphocyte line, growing in suspension and widely used to study B-cell signaling, lymphomagenesis, and drug responses. Their expression of CD19, CD20, and other B-cell markers, along with EBV-driven pathways, provides a relevant model for oncogenesis and immune recognition studies.
EPHX1 encodes microsomal epoxide hydrolase, which catalyzes the hydrolysis of xenobiotic and endogenous epoxide moieties to diols, a key reaction in phase I detoxification and xenobiotic metabolism. Its transcription is regulated by NRF2 and AhR in response to oxidative stress and phenobarbital. The enzyme cooperates with cytochrome P450s such as CYP1A1 and CYP1B1, which generate epoxide substrates, and with glutathione S-transferases and UDP-glucuronosyltransferases that process the resulting diols. In arachidonic acid metabolism, EPHX1 converts epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids, attenuating their vasodilatory and anti-inflammatory functions while potentially activating NF-??B-driven inflammatory programs.
In Raji Burkitt’s lymphoma cells, EPHX1 knockout disrupts epoxide metabolism, potentially increasing sensitivity to epoxide-containing chemotherapeutics and altering endogenous EET levels that modulate survival, proliferation, and inflammatory signaling. Loss of epoxide hydrolase activity may lead to accumulation of reactive epoxides, enhancing oxidative stress and DNA damage, while preserving EET-mediated effects on NF-??B activity and apoptosis. This model thus enables dissection of EPHX1’s contribution to lymphomagenesis and drug resistance mechanisms.
Applications include xenobiotic metabolism studies using viability assays with epoxide substrates, gene expression profiling via RT-qPCR and RNA-seq, and oxidative stress assessment by ROS detection. The cells are also useful for drug sensitivity testing with lymphoma-relevant agents and for investigating EET/DHET signaling by flow cytometry for apoptosis and proliferation. For validation data or custom application inquiries, please contact Ascent Research.
